Table 8. Effect of TMZ treatment on hearts subjected to AHF—Obese luteal females (n = 6).
| Treatment group | Heart rate (%) | Sig. | LVDevP (%) | Sig. |
| Control | 38.49 ± 10.56 | ns | 1725.24 ± 397.04 |
** |
| TMZ at CAHF | 36.99 ± 3.84 | 3199.25 ± 743.72 | ||
| TMZ at RAHF | 32.55 ± 2.48 | 5400.37 ± 887.21 | ||
| Treatment group | LVEDP (%) | Sig. | LVESP (%) | Sig. |
| Control | 574.86 ± 308.07 | ns | 521.49 ± 240.36 | ns |
| TMZ at CAHF | 140.93 ± 11.62 | 145.23 ± 12.91 | ||
| TMZ at RAHF | 126.83 ± 7.53 | 132.12 ± 9.01 |
Data represent the last ten minutes of the RAHF phase and expressed as a percentage of CAHF. Significance is expressed as **p<0.01 versus control. LVDevP: left ventricular developed pressure; LVEDP: left ventricular end diastolic pressure; LVESP: left ventricular end systolic pressure; CAHF: critical acute heart failure; RAHF: recovery acute heart failure; Sig.: significance; ns: not significant.